Atlas Trials

A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL)

Clinical trial NCT03797456 · COMPLETED

Trial details

NCT number
NCT03797456
Sponsor
Beijing InnoCare Pharma Tech Co., Ltd.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
MZL
Start date
2019-04-01
Primary completion
2023-12-27
Enrollment
111

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.